2025 United Kingdom Bioprocess Technology Market Revenue Opportunities Report
Description
The 2025 United Kingdom Bioprocess Technology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Bioprocess Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest UK companies actively participating in the bioprocess technology market include Oxford Nanopore Technologies, Autolus Therapeutics, Amphista Therapeutics, and Verona Pharma. Oxford Nanopore leads in real-time DNA and RNA sequencing technologies, integrating proteomics to enhance biopharmaceutical and healthcare research with revenues of £183 million in 2024. Autolus focuses on CAR-T cell therapies for cancer, recently obtaining FDA approval for a key product and partnering with major firms like Moderna and Bristol Myers Squibb. Amphista specializes in targeted protein degradation for cancer and neurological diseases, backed by a $30 million upfront deal from Bristol Myers Squibb. Verona Pharma, valued over $5 billion, develops novel respiratory treatments with blockbuster potential.
These companies exemplify the UK's strength in biotechnology across drug discovery, gene therapy, and bioprocessing innovations. They contribute to a UK biotech sector worth billions with a significant R&D focus and cutting-edge platforms enhancing industrial bioprocess technologies. Their collaborations with pharmaceutical majors and investment in AI and cell therapies position the UK as a global leader in biotech innovation and industrial bioprocess applications.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Bioprocess Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest UK companies actively participating in the bioprocess technology market include Oxford Nanopore Technologies, Autolus Therapeutics, Amphista Therapeutics, and Verona Pharma. Oxford Nanopore leads in real-time DNA and RNA sequencing technologies, integrating proteomics to enhance biopharmaceutical and healthcare research with revenues of £183 million in 2024. Autolus focuses on CAR-T cell therapies for cancer, recently obtaining FDA approval for a key product and partnering with major firms like Moderna and Bristol Myers Squibb. Amphista specializes in targeted protein degradation for cancer and neurological diseases, backed by a $30 million upfront deal from Bristol Myers Squibb. Verona Pharma, valued over $5 billion, develops novel respiratory treatments with blockbuster potential.
These companies exemplify the UK's strength in biotechnology across drug discovery, gene therapy, and bioprocessing innovations. They contribute to a UK biotech sector worth billions with a significant R&D focus and cutting-edge platforms enhancing industrial bioprocess technologies. Their collaborations with pharmaceutical majors and investment in AI and cell therapies position the UK as a global leader in biotech innovation and industrial bioprocess applications.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
